Ascendis Pharma (Nasdaq:ASND) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ASND 주식 개요

바이오 제약 회사인 아센디스 파마 A/S는 미충족 의료 수요에 대한 치료법 개발에 주력하고 있습니다.

ASND 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	5/6
과거 실적	0/6
재무 상태	0/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 80.2% 에서 거래

수익은 매년 67.85% 증가할 것으로 예상됩니다.

위험 분석

마이너스 주주 지분

cash runway 경력이 1년 미만입니다.

지난 1년 동안 주주가 희석되었습니다.

Ascendis Pharma A/S 경쟁사

Global Blood Therapeutics

NasdaqGS:GBT

US$4.6b

Rhythm Pharmaceuticals

NasdaqGM:RYTM

US$2.5b

Krystal Biotech

NasdaqGS:KRYS

US$5.2b

Legend Biotech

NasdaqGS:LEGN

US$8.1b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Ascendis Pharma
과거 주가
현재 주가	US$136.38
52주 최고치	US$161.00
52주 최저치	US$85.29
베타	0.59
11개월 변경	0.95%
3개월 변경 사항	-6.77%
1년 변경 사항	54.73%
33년 변화	1.90%
5년 변화	19.78%
IPO 이후 변화	624.27%

최근 뉴스 및 업데이트

Recent updates

Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Oct 05

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

Jun 27

Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week

May 05

Is Ascendis Pharma (NASDAQ:ASND) Using Debt In A Risky Way?

Feb 18

Is Ascendis Pharma (NASDAQ:ASND) A Risky Investment?

Sep 24

Ascendis Pharma: TransCon CNP Data Coming Q4

Sep 15

Ascendis Pharma seeks FDA nod for its parathyroid hormone restorer TransCon PTH

Aug 31

Ascendis Pharma Q2 results beat buoyed by strong sales of growth hormone drug Skytrofa

Aug 11

Ascendis Pharma: Institutional Buying Values Dutch Biotech Best-Now Cap-Gain Prospect

Aug 03

Here's Why Ascendis Pharma (NASDAQ:ASND) Can Manage Its Debt Despite Losing Money

Jun 10

Ascendis Pharma: Biotech Bear Provides Attractive Entry Point

May 09

Ascendis: Institutional Buying Activity Now Seen As Good Value By Market-Makers

Apr 29

Ascendis Pharma A/S' (NASDAQ:ASND) Intrinsic Value Is Potentially 51% Above Its Share Price

Feb 24

Is Ascendis Pharma (NASDAQ:ASND) In A Good Position To Invest In Growth?

Jan 07

Ascendis: Danish Biotech With Thin Audience Now Seen As Good Value By Market-Makers

Dec 30

Ascendis Pharma A/S' (NASDAQ:ASND) Intrinsic Value Is Potentially 97% Above Its Share Price

Sep 24

주주 수익률

	ASND	US Biotechs	US 마켓
7D	5.4%	-1.6%	-0.06%
1Y	54.7%	10.4%	20.5%

수익률 대 산업: ASND 지난 1년 동안 6.7 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: ASND 지난 1년 동안 23.3 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is ASND's price volatile compared to industry and market?
ASND volatility
ASND Average Weekly Movement	5.3%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.9%

안정적인 주가: ASND 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: ASND 의 주간 변동성( 5% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2006	879	Jan Mikkelsen	ascendispharma.com

바이오 제약 회사인 아센디스 파마 A/S는 미충족 의료 수요에 대한 치료법 개발에 주력하고 있습니다. 성장호르몬 결핍증(GHD) 환자 치료를 위한 스카이트로파를 제공합니다. 또한 임상 개발 중인 3개의 독립적인 내분비학 희귀질환 치료제 후보물질 파이프라인을 개발하고 있으며, 종양학 치료제 후보물질 개발에도 주력하고 있습니다.

Ascendis Pharma A/S 기본 사항 요약

Ascendis Pharma 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ASND 기본 통계
시가총액	US$7.82b
수익(TTM)	-US$537.30m
수익(TTM)	US$352.46m

22.2x

P/S 비율

-14.6x

P/E 비율

ASND 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ASND 손익 계산서(TTM)
수익	€329.02m
수익 비용	€47.34m
총 이익	€281.68m
기타 비용	€783.25m
수익	-€501.57m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-8.75
총 마진	85.61%
순이익 마진	-152.44%
부채/자본 비율	-239.8%

ASND 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ASND 주식 개요

보상

위험 분석

Ascendis Pharma A/S 경쟁사

NasdaqGS:GBT

US$4.6b

NasdaqGM:RYTM

US$2.5b

NasdaqGS:KRYS

US$5.2b

NasdaqGS:LEGN

US$8.1b

가격 내역 및 성능

최근 뉴스 및 업데이트

Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

New minor risk - Shareholder dilution

Ascendis Pharma A/S Announces 2-Year Results from A Post-Hoc Analysis of the Company's Phase 3 PaTHway Trial

Consensus EPS estimates fall by 13%, revenue upgraded

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Ascendis Pharma A/S Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults with Hypoparathyroidism

New minor risk - Shareholder dilution

Ascendis Pharma A/S Announces 2-Year Results from A Post-Hoc Analysis of the Company's Phase 3 PaTHway Trial

Consensus EPS estimates fall by 13%, revenue upgraded

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ascendis Pharma A/S, Annual General Meeting, May 30, 2024

Ascendis Pharma A/S to Report Q1, 2024 Results on May 02, 2024

Ascendis Pharma A/S Announces United Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Some Confidence Is Lacking In Ascendis Pharma A/S' (NASDAQ:ASND) P/S

Ascendis Pharma A/S Appoints Mads Bodenhoff as Senior Vice President, Finance Principal Accounting Officer

Executive VP notifies of intention to sell stock

Consensus estimates of losses per share improve by 17%

President notifies of intention to sell stock

President notifies of intention to sell stock

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Ascendis Pharma A/S to Report Fiscal Year 2023 Results on Feb 07, 2024

Consensus revenue estimates increase by 12%

Ascendis Pharma's Ambitious Vision 2030

Ascendis Pharma A/S Introduces Vision 2030

New minor risk - Profitability

What Ascendis Pharma A/S' (NASDAQ:ASND) 29% Share Price Gain Is Not Telling You

Ascendis Pharma A/S Announces New Analyses from Blinded and Ongoing Open-Label Extension Portions of ACcomplisH

Ascarma A/S Announces TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

FDA Accepts for Review Resubmitted NDA for Transcon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism

President notifies of intention to sell stock

Ascendis Pharma A/S Announces European Commission Approval of YORVIPATH (Palopegteriparatide) for Treatment of Adults with Chronic Hypoparathyroidism

Ascendis Pharma A/S Resubmits NDA for TransCon™? PTH to the U.S. FDA

New minor risk - Profitability

New major risk - Negative shareholders equity

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

New major risk - Negative shareholders equity

Ascendis Presents Updated and New Transco Il-2 ß/? Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types At Esmo 2023

Consensus revenue estimates decrease by 11%

Ascendis Pharma A/S' (NASDAQ:ASND) Popularity With Investors Is Under Threat From Overpricing

Ascendis Pharma A/S Presents Transcon Pth Data At the American Thyroid Association Annual Meeting

Key Executive notifies of intention to sell stock

Ascendis Pharma A/S Presents Results from Long-Term enliGHten Trial of TransCon hGH in Pediatric Growth Hormone Deficiency

Ascendis Pharma Launches SKYTROFA (Lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency

Ascendis Pharma A/S Receives Positive CHMP Opinion for Transcon PTH (Palopegteriparatide) for Adults with Chronic Hypoparathyroidism

Consensus revenue estimates increase by 24%

Independent Chairman notifies of intention to sell stock

New major risk - Financial position

Ascendis Pharma A/S Announces New Post Hoc Analysis Showing Adults with Hypoparathyroidism Treated with TransCon PTH

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ascendis Pharma A/S to Report Q2, 2023 Results on Sep 05, 2023

Is Ascendis Pharma (NASDAQ:ASND) Using Debt Sensibly?

Aendis Pharma A/S Reports One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

Ascendis Pharma Showcases its Latest Endocrinology Programs, Data, and Research at ENDO 2023

Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates

Analysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This Week

Ascendis Pharma A/S, Annual General Meeting, May 30, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Now 20% undervalued after recent price drop

Consensus revenue estimates decrease by 14%

President notifies of intention to sell stock

Is Ascendis Pharma (NASDAQ:ASND) Using Debt In A Risky Way?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ascendis Pharma A/S to Report Fiscal Year 2022 Results on Feb 16, 2023